1.19
-0.01 (-0.83%)
Penutupan Terdahulu | 1.20 |
Buka | 1.20 |
Jumlah Dagangan | 1,384,912 |
Purata Dagangan (3B) | 3,098,719 |
Modal Pasaran | 260,289,920 |
Harga / Jualan (P/S) | 7.78 |
Harga / Buku (P/B) | 0.700 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Aug 2025 |
EPS Cair (TTM) | -1.22 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 23.07% |
Nisbah Semasa (MRQ) | 9.71 |
Aliran Tunai Operasi (OCF TTM) | -197.33 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.65 M |
Pulangan Atas Aset (ROA TTM) | -28.92% |
Pulangan Atas Ekuiti (ROE TTM) | -59.60% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Allogene Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 0.5 |
Purata Bergerak Teknikal | 3.5 |
Osilator Teknikal | -2.0 |
Purata | 1.50 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 17.74% |
% Dimiliki oleh Institusi | 80.54% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 10.00 (Truist Securities, 740.34%) | Beli |
10.00 (RBC Capital, 740.34%) | Beli | |
Median | 9.00 (656.30%) | |
Rendah | 4.00 (Citigroup, 236.13%) | Beli |
Purata | 8.17 (586.56%) | |
Jumlah | 6 Beli | |
Harga Purata @ Panggilan | 0.973 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Citigroup | 15 May 2025 | 4.00 (236.13%) | Beli | 1.09 |
Baird | 14 May 2025 | 9.00 (656.30%) | Beli | 0.950 |
Oppenheimer | 14 May 2025 | 9.00 (656.30%) | Beli | 0.950 |
Piper Sandler | 14 May 2025 | 7.00 (488.24%) | Beli | 0.950 |
RBC Capital | 14 May 2025 | 10.00 (740.34%) | Beli | 0.950 |
Truist Securities | 14 May 2025 | 10.00 (740.34%) | Beli | 0.950 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |